Veru (STU:FMW) Short-Term Debt : €0.88 Mil (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Veru Short-Term Debt?

Veru's Short-Term Debt for the quarter that ended in Mar. 2024 was €0.88 Mil.

Veru's quarterly Short-Term Debt declined from Sep. 2023 (€0.81 Mil) to Dec. 2023 (€0.76 Mil) but then increased from Dec. 2023 (€0.76 Mil) to Mar. 2024 (€0.88 Mil).

Veru's annual Short-Term Debt declined from Sep. 2021 (€2.75 Mil) to Sep. 2022 (€1.18 Mil) and declined from Sep. 2022 (€1.18 Mil) to Sep. 2023 (€0.81 Mil).

Veru Short-Term Debt Historical Data

The historical data trend for Veru's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Veru Short-Term Debt Chart

Veru Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Short-Term Debt

Get a 7-Day Free Trial

4.89

5.89

2.75

1.18

0.81

Veru Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Debt	Get a 7-Day Free Trial															1.27	0.98	0.81	0.76	0.88

Veru Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Veru Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Veru's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Veru (STU:FMW) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Veru Inc (STU:FMW) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

VERU:USA FMW:Germany

Address

2916 North Miami Avenue, Suite 1000, Miami, FL, USA, 33127

Website

https://www.verupharma.com

Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology and acute respiratory distress syndrome (ARDS). The company is also in the late stage development of certain drugs for management of breast and prostate cancers. It also has a sexual health program which includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in single segment and generates revenue from USA which is the key revenue generating market, South Africa and other regions.

Veru (STU:FMW) Headlines

No Headlines